Login to Your Account



Orphan Europe, Erytech Ink Deal for New Asparaginase

By Cormac Sheridan
Staff Writer

Wednesday, December 5, 2012
A recent European licensing deal between Orphan Europe and Erytech Pharma SA on a novel formulation of asparaginase, called Graspa, is further evidence of the commercial revitalization of a long-established treatment in hematologic cancer.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription